Evidence map›Paper›PMID 16953241›Full record

Trial reportBritish journal of cancer2006

Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide.

J Cebon, M Findlay, C Hargreaves, M Stockler, P Thompson, M Boyer, S Roberts, A Poon, A M Scott, V Kalff and 13 more

Erratum issued Registry-linked trialOpen access · hybridAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in British journal of cancer, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT00495846 (Treatment of Advanced Hepatocellular Carcinoma With Depot Somatostatin Analogues), which is not on this map. Cited by 24 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 2 pooled it
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00495846 phase2 / phase3completednot on this mapstarted 2007, after this paper: background citation

Treatment of Advanced Hepatocellular Carcinoma With Depot Somatostatin Analogues: a Pilot Prospective Study Based on Somatostatin Receptors Tumors Expression

TypeinterventionalSponsorFederico II UniversityRan2007 to 2008Enrolled25ConditionsAdvanced Hepatocellular CarcinomaArmsOctreotide-LAR, Lanreotide Autogel, Locoregional treatments
3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Health-related quality of life in primary hepatic cancer: a systematic review assessing the methodological properties of instruments and a meta-analysis comparing treatment strategies.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2021
    Pooled it
  2. Somatostatin analogues in advanced hepatocellular carcinoma: an updated systematic review and meta-analysis of randomized controlled trials.Medical science monitor : international medical journal of experimental and clinical research · 2011
    Pooled it
  3. Trial
  4. Trial
  5. Octreotide and hepatocellular carcinoma.British journal of cancer · 2007
    Trial
  6. Review
  7. Article
  8. Review
  9. Somatostatin and Somatostatin Receptors in Tumour Biology.International journal of molecular sciences · 2023
    Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Quality of life and hepatocellular carcinoma.Journal of gastrointestinal oncology · 2014
    Review
  17. Review
  18. Review
  19. [Diagnosis of and therapy for hepatocellular carcinoma].Zeitschrift fur Gastroenterologie · 2013
    Article
  20. Article
4 · The record

Corrections and comments

  • Commented on by
  • Erratum issued
    Findlay, M [added]; Hargreaves, C [added]; Stockler, M [added]; Thompson, P [added]; Boyer, M [added]; Roberts, S [added]; Poon, A [added]; Scott, A M [added]; Kalff, V [added]; Garas, G [added]; Dowling, A [added]; Crawford, D [added]; Ring, J [added]; Ba
5 · Who and what money

Authors and funding

23 authors at 2 institutions in 1 country.

J CebonAGITG Trial Coordinating Centre, NHMRC Clinical Trials Centre, University of Sydney, Locked Bag 77, Camperdown, NSW 1450, Australia. jonathan.cebon@ludwig.edu.au
M Findlay
C Hargreaves
M Stockler
P Thompson
M Boyer
S Roberts
A Poon
A M Scott
V Kalff
G Garas
A Dowling
D Crawford
J Ring
R Basser
A Strickland
G Macdonald
M Green
A Nowak
B Dickman
H Dhillon
V Gebski
Australasian Gastro-Intestinal Trials Group (AGITG) Ag0001H Investigators
Cooperative Trials Group for Neuro-Oncology · AUNational Health and Medical Research Council · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Octreotide may extend survival in hepatocellular carcinoma (HCC). Forty-one per cent of HCCs have high-affinity somatostatin receptors. We aimed to determine the feasibility, safety, and activity of long-acting octreotide in advanced HCC; to identify the best method for assessing somatostatin receptor expression; to relate receptor expression to clinical outcomes; and to evaluate toxicity. Sixty-three patients with advanced HCC received intramuscular long-acting octreotide 20 mg monthly until progression or toxicity. Median age was 67 years (range 28-81 years), male 81%, Child-Pugh A 83%, and B 17%. The aetiologies of chronic liver disease were alcohol (22%), viral hepatitis (44%), and haemochromatosis (6%). Prior treatments for HCC included surgery (8%), chemotherapy (2%), local ablation (11%), and chemoembolisation (6%). One patient had an objective partial tumour response (2%, 95% CI 0-9%). Serum alpha-fetoprotein levels decreased more than 50% in four (6%). Median survival was 8 months. Thirty four of 61 patients (56%) had receptor expression detected by scintigraphy; no clear relationship with clinical outcomes was identified. There were few grade 3 or 4 toxicities: hyperglycaemia (8%), hypoglycaemia (2%), diarrhoea (5%), and anorexia (2%). Patients reported improvements in some symptoms, but no major changes in quality of life were detected. Long-acting octreotide is safe in advanced HCC. We found little evidence of anticancer activity. A definitive randomised trial would identify whether patients benefit from this treatment in other ways.

Indexed as

Quality of LifeAdultAgedAged, 80 and overAntineoplastic Agents, HormonalCarcinoma, HepatocellularChromogranin AChromograninsDelayed-Action PreparationsFemaleHumansImmunohistochemistryLiver NeoplasmsMaleMiddle AgedOctreotideAntineoplastic Agents, HormonalChromogranin AChromograninsDelayed-Action PreparationsOctreotideReceptors, Somatostatin

Identifiers

PMID16953241
PMCPMC2360532
OpenAlexW2096562720

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.